EXTAVIA Powder and solvent for solution for injection Ref.[8863] Active ingredients: Interferon beta-1b

Source: European Medicines Agency (EU)  Revision Year: 2019  Publisher: Novartis Europharm Limited, Vista Building, Elm Park, Merrion Road, Dublin 4, Ireland

Product name and form

Extavia 250 microgram/ml powder and solvent for solution for injection.

Pharmaceutical Form

Powder and solvent for solution for injection.

Powder – white to off-white in colour.

Solvent – clear/colourless solution.

Qualitative and quantitative composition

Extavia contains 300 microgram (9.6 million IU) of recombinant interferon beta-1b per vial*.

After reconstitution, each ml contains 250 microgram (8.0 million IU) of recombinant interferon beta1b.

* produced by genetic engineering from strain of Escherichia coli.

For the full list of excipients, see section 6.1.

Active Ingredient Description
Interferon beta-1b

Interferon beta-1b has been shown to possess both antiviral and immunoregulatory activity. The mechanisms by which interferon beta-1b exerts its actions in multiple sclerosis are not clearly understood. However, it is known that the biological response-modifying properties of interferon beta-1b are mediated through its interactions with specific cell receptors found on the surface of human cells.

List of Excipients

Powder:

Human albumin
Mannitol (E421)

Solvent:

Sodium chloride
Water for injection

Pack sizes and marketing

Powder: 3 ml vial (clear type I glass) with a butyl rubber stopper (type I) and aluminium overseal containing 300 microgram (9.6 million IU) of (recombinant interferon beta-1b) powder.

Solvent: 2.25 ml graduated (with dose marks of: 0.25 ml, 0.5 ml, 0.75 ml, 1.0 ml) pre-filled syringe (type I glass) with 1.2 ml solvent.

Pack sizes:

Pack containing 5 vials with powder and 5 pre-filled syringes with solvent
Pack containing 14 vials with powder and 14 pre-filled syringes with solvent
Pack containing 15 vials with powder and 15 pre-filled syringes with solvent
Pack containing 14 vials with powder and 15 pre-filled syringes with solvent

3-month multipack containing 42 (3x14) vials with powder and 42 (3x14) pre-filled syringes with solvent
3-month multipack containing 45 (3x15) vials with powder and 45 (3x15) pre-filled syringes with solvent
3-month multipack containing 42 (3x14) vials with powder and 45 (3x15) pre-filled syringes with solvent

Not all pack sizes may be marketed.

Marketing authorization holder

Novartis Europharm Limited, Vista Building, Elm Park, Merrion Road, Dublin 4, Ireland

Marketing authorization dates and numbers

EU/1/08/454/008-014

Date of first authorisation: 20 May 2008
Date of latest renewal: 20 May 2013

Drugs

Drug Countries
EXTAVIA Austria, Brazil, Canada, Cyprus, Estonia, Spain, France, Croatia, Ireland, Lithuania, Poland, United Kingdom

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.